Azitra Q1 FY26 net loss widens to $3.9 million; G&A expenses rise to $2.4 million

Azitra Inc.

Azitra Inc.

AZTR

0.00
  • Azitra posted a net loss of $3.9 million for quarter ended March 31, 2026, widening from $3.1 million year earlier.
  • R&D expense rose to $1.6 million from $1.3 million, while G&A costs increased to $2.4 million from $1.9 million.
  • Cash and cash equivalents totaled $10.1 million at quarter-end.
  • Clinical footprint expanded for ATR-04 Phase 1/2 trial in EGFRi-associated rash with addition of MD Anderson Cancer Center; first-cohort topline data expected in H2 2026.
  • Topline data for ATR-12 Phase 1b trial in Netherton syndrome anticipated H2 2026; management cited a strengthened balance sheet and multiple near-term catalysts.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001701478-26-000029), on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.